New therapeutic applications of ozenoxacin in superficial skin infections

Gema García Ron, María Villa Arranz

https://doi.org/10.4081/dr.2021.9289

Supplementary Material

Table 1. **Causal agents of Skin and Soft tissue infections**[6]

Clinical entity	Frequent microorganisms	Less frequent or rare
Subcutaneous abscesses	**S. aureus**. Mixed aerobic/anaerobic flora	***S. pyogenes***
Carbuncle and cutaneous anthrax	*B. anthracis*	
Cellulitis (Erysipelas and lymphangitis)	***S. aureus. S. pyogenes***	*Streptococci B, C and G. S. pneumoniae. H. influenzae type B. E. coli* and other *Enterobacteriaceae A. hydrophila. Y. enterocolitica. V. vulnificus* and other vibrios.
Cellulitis secondary to animal bite	Oropharyngeal aerobic and anaerobic pharyngeal flora. ***S. aureus***, *S. intermedius. Pasterurella*	*BGN. Actinobacillus. Bergelyella zoohelcum. Capnocytophaga canimorsus*. Other microorganisms.
Necrotizing cellulitis and fasciitis	Mixed aerobic and anaerobic flora. **S. pyogenes**. *Clostridium.*	**S. aureus** and other bacteria
Ecthyma	***S. pyogenes****. P. aeruginosa*	*Aeromonas.* ***S. aureus***
Perianal dermatitis	***S. pyogenes***	***S. aureus***
Erythrasma	*C. minutissimum*	
Folliculitis, furuncle	***S. aureus***	*P. aeruginosa. C. albicans. M. furufur*
Non-bullous impetigo	***S. aureus, S. pyogenes.***	*Bacillus cereus*
Bullous impetigo and Scalded skin syndrome	***S. aureus***	
Hidrosadenitis suppurativa	***S. aureus***	*Oropharyngeal anaerobic flora. BGN. S. viridans.*
Omphalitis	***S. aureus. S. pyogenes***	*BGN*
Paronychia	***S. aureus***. Oropharyngeal flora	*E. corrodens. HSV. Enterobacteriae*
Pyomyositis	***S. aureus***	***S. pyogenes.***

Table 2 Characteristics of the different topical antibiotics[6]

	Mechanism of action	Antibacterial activity	Pediatric age	Posology
Mupirocin	Bacteriostatic/bactericidal	Active in front of *S. aureus* and *S. pyogenes*	No age limit in SmPC	t.i.d. 7-12 days
Fusidic Acid	Bacteriostatic/bactericidal	Active in front of *S. aureus* and *S. pyogenes*	No age limit in SmPC	t.i. d. 7-12 days
Retapamulin	Bacteriostatic	Active in front of Gram-positive cocci. Not on MRSA	From 9 months on	b.i.d. 5 days
Ozenoxacin	Bactericidal	Active on *S. aureus* (including MRSA), *S. pyogenes* and some Gram-negative bacteria.	From 6 months on in EU. From 2 months on in USA and Canada.	b.i.d. 5 days

Table 3: Baseline characteristics of the patients

Characteristics	
Age (years)	8.3 (range 3-14)
Sex, male: female	12 (75%): 4 (25%)
Clinical picture	
• Paronyquia, whitlows	13 (81.25%)
• Folliculitis	2 (12.5%)
• Piercing infection	1 (6.25%)

Pictures of the cases at baseline (left) and after 5 days twice a day ozenoxacin therapy (right)

Patient 1






Patient 4




Patient 5


Patient 6


Patient 7

Patient 8

Patient 11

Patient 12




Patient 14




Patient 16